The short answer
Goldenseal can alter metformin exposure, but the effect depends on the product, metformin dose and formulation. A later study in people with diabetes did not find worse average glucose control. Review co-use before starting goldenseal; there is no proven spacing interval that makes the combination predictable.
What this answer covers
Oral Hydrastis canadensis root products with metformin; whole root, characterized root capsules and purified berberine are not interchangeable.
- Supplement or preparation
- Hydrastis canadensis
- Medication ingredient
- metformin
Why might the two affect each other?
In 16 healthy volunteers, a characterized goldenseal root product reduced exposure to a 50 mg metformin probe dose by about 23%. Kidney clearance was unchanged, suggesting an effect on absorption rather than faster kidney removal. The probe dose was much lower than usual diabetes treatment, so that percentage cannot simply be applied to a prescribed daily dose.
What happened in people with diabetes?
A later study followed 22 adults using metformin 500-2,550 mg/day. The average exposure change was within the study’s no-effect range. Larger reductions appeared at lower doses and with immediate-release metformin; the high-dose group had no mean reduction. These were small subgroups, and the study was not designed to establish a separate safe schedule for each formulation.
Did goldenseal make metformin work less well?
Not demonstrably in that short patient study. HbA1c decreased from 6.8% to 6.5% in the 15 people with evaluable results, while other glucose measures did not clearly improve. The short duration, fixed study sequence and possible behavior changes prevent treating this as proof of benefit. A lower blood drug concentration does not by itself establish worse diabetes control.
Should I avoid it or leave a gap?
The original healthy-volunteer researchers advised against unsupervised goldenseal supplementation with metformin. Neither study tested a protective dosing gap, and the whole-root patient product does not cover every tea, extract or berberine tablet. Discuss the exact product and whether additional glucose checks are appropriate before starting or stopping it.
Evidence and practical considerations
Timing & monitoring
Goldenseal can alter metformin exposure, but the effect depends on the product, metformin dose and formulation. A later study in people with diabetes did not find worse average glucose control. Review co-use before starting goldenseal; there is no proven spacing interval that makes the combination predictable.
- Exact scope
- characterized oral Hydrastis canadensis root capsules; whole-root patient trial distinguished from other extracts with oral metformin; hydrochloride IR, ER or low-dose solution retained source by source
- Medication form and route
- oral
- Timing or duration
- Five-day exposure in healthy volunteers and acute/28-day exposure in adults with diabetes. No preventive interval tested.
What remains uncertain
- Product and dose/formulation dependence, small subgroups and exploratory glucose endpoints prevent a blanket treatment-failure or spacing claim.
Factors that may matter: exact preparation and dose; medication formulation and duration; other medicines and underlying conditions; source population and measured outcome.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving oral extended-release metformin hydrochloride.
Advises annual hematologic assessment and B12 measurements every 2-3 years. Hypoglycemia is uncommon with metformin alone but risk is greater with insulin or secretagogues and other circumstances.
How this applies: Exact metformin parent RxCUI 6809 with hydrochloride formulation retained. Monitoring and general precautions only unless B12 is the counterparty. Counterparty scope for this package: characterized oral Hydrastis canadensis root capsules; whole-root patient trial distinguished from other extracts.
Extended-release label is not a study of immediate-release interaction kinetics; no aloe, chromium or goldenseal-specific effect or interval quantified.
Source 2: original human pharmacokinetic study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy adults, 8 men and 8 women, completed open-label fixed-sequence crossover.
Metformin AUC fell 23% and peak 27%; half-life and renal clearance unchanged. No glucose efficacy endpoint at this subtherapeutic metformin dose.
How this applies: Exact metformin and characterized Hydrastis root product. Preserve the authors’ dual root-extract/dried-root descriptions; do not infer generic extract equivalence. Counterparty scope for this package: characterized oral Hydrastis canadensis root capsules; whole-root patient trial distinguished from other extracts.
One characterized product and healthy volunteers; laboratory methanol extract prepared separately and not the consumed product. No proof for every extraction process or for clinical treatment failure.
Source 3: original human pharmacokinetic crossover study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 22 adults with type 2 diabetes, 12 men and 10 women; immediate-release or extended-release metformin.
Aggregate AUC ratio 0.93 (90% CI 0.86-1.01) met no-effect criterion. Larger exposure reductions at lower doses and immediate release; no mean high-dose reduction. HbA1c fell 6.8% to 6.5% in 15 evaluable participants; other glucose markers did not corroborate improvement.
How this applies: Direct whole-root/metformin study. It limits claims that lower measured exposure inevitably worsens diabetes control; extraction-node use is indirect. Counterparty scope for this package: characterized oral Hydrastis canadensis root capsules; whole-root patient trial distinguished from other extracts.
Small nonrandomized dose/formulation groups; fixed last chronic arm, participation bias and no power for clinical glycemic outcomes. Whole root, not interchangeable with all extracts.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and current labels checked; complete private article and exact-current-claim adjudications prepared. | |
| Research summary published |
Article revision: 3c1afd6b0b56a8b2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.